Drug Trial Radar · NCT00313820
Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
Last checked: Nov 20, 2026Latest source record: Feb 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Aug 2006
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP)
Conditions
- Central Neuropathic Pain
Interventions
PregabalinDrug
Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
PlaceboDrug
Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS)Time frame: Up to Week 12
Locations
33 sites in 11 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
East Gosford, New South Wales, Australia
Pfizer Investigational Site
St Leonards, New South Wales, Australia
Pfizer Investigational Site
Warrawong, New South Wales, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Footscray, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Guangzhou, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
New Territories, Hong Kong
Pfizer Investigational Site
Bangalore, India
Pfizer Investigational Site
Bangalore, India
Pfizer Investigational Site
Chennai, India
Pfizer Investigational Site
Lucknow, India
Pfizer Investigational Site
New Delhi, India
Pfizer Investigational Site
Jakarta, Indonesia
Pfizer Investigational Site
Surabaya, Indonesia
Pfizer Investigational Site
George Town, Malaysia
Pfizer Investigational Site
Kuala Lumpur, Malaysia
Pfizer Investigational Site
Kuala Selangor, Malaysia
Pfizer Investigational Site
Karachi, Pakistan
Pfizer Investigational Site
Karachi, Sindh, Pakistan
Pfizer Investigational Site
Manila, Philippines
Pfizer Investigational Site
Manila, Philippines
Pfizer Investigational Site
Seoul, South Korea
Pfizer Investigational Site
Taichung, Taiwan
Pfizer Investigational Site
Taipei, Taiwan
Pfizer Investigational Site
Gueishan Shiang, Taoyuan Hsien, Taiwan
Pfizer Investigational Site
Bangkok, Thailand
Pfizer Investigational Site
Ratchatewee, Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.